Different regions of the brain and spinal cord house different, specialized cells. Neuralstem’s technology enables the isolation and expansion of human neural stem cells from each of these regions of the developing central nervous system (CNS) in virtually unlimited numbers from a single donated tissue. More

Neuralstem’s technology uniquely enables the creation of stable neural stem cell lines from the human hippocampus, a part of the brain involved in memory and the generation of new neurons. From these cell lines, the company can create practically unlimited amounts of hippocampal neural stem cells. More

    • Neuralstem Announces Presentations at Upcoming Scientific Conferences 11.02.16

      GERMANTOWN, Md., November 2, 2016 -- Neuralstem, Inc. (Nasdaq: CUR), a biopharmaceutical company focused on the development of central nervous system therapies based on its neural stem cell technology, announced poster presentations at two upcoming scientific conferences. Presentations include preclinical data in both of the company’s stem cell and small molecule platforms at the Society for Neurosciences Annual Meeting, as well as the American College of Toxicology Annual Meeting. Following is a schedule of relevant presentations: More


    • Neuralstem Presents NSI-189 Preclinical Neurocognitive Benefits at the Radiation Research Society Annual Meeting

      NSI-189 Shows Reserval of Radiation-induced Cognitive Deficits 10.20.16

      GERMANTOWN, Md., Oct 20, 2016 -- Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical company focused on the development of central nervous system therapies based on its neural stem cell technology, announced the presentation of the poster entitled, “Reversal of radiation-induced cognitive impairment by oral administration of a neurogenic small molecule compound NSI-189,” at the Radiation Research Society Annual Meeting on October 19th. The preclinical study data concluded that NSI-189 provided treatment benefits in the reversal of radiation-induced cognitive deficits. More


    • Neuralstem Receives $20,000,000 Strategic Investment from Tianjin Pharmaceutical Group 9.12.16

      GERMANTOWN, Md., Sept. 12, 2016 (GLOBE NEWSWIRE) -- Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical company focused on the development of central nervous system therapies based on its neural stem cell technology, today announced that on September 7, 2016, it entered into definitive agreements with Tianjin Pharmaceutical Holding Group for the private placement of common stock and convertible preferred stock for gross proceeds of $20,000,000. More


    • Neuralstem Announces NSI-189 Shows Enhancement of Long-Term Potentiation In Vitro 6.21.16

      GERMANTOWN, Md., June 21, 2016 (GLOBE NEWSWIRE) -- Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical company focused on the development of central nervous system therapies based on its neural stem cell technology, announced that new in vitro data on NSI-189 provide insight into the neurogenic drug’s mode of action. More